A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumor s and hematologic malignancies

Chemotherapy-induced thrombocytopenia (CIT) frequently complicates cancer treatment causing chemotherapy treatment delays, dose reductions, and discontinuation. There is no US Food and Drug Administration (FDA)-approved agent available to manage CIT. This study retrospectively evaluated patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Samkari, Hanny, Parnes, Aric D., Goodarzi, Katayoon, Weitzman, James I., Connors, Jean M., Kuter, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018116/
https://www.ncbi.nlm.nih.gov/pubmed/32499239
http://dx.doi.org/10.3324/haematol.2020.251900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018116/
https://www.ncbi.nlm.nih.gov/pubmed/32499239
http://dx.doi.org/10.3324/haematol.2020.251900

Ejemplares similares